Serum thymidine kinase (TK) evaluation in HIV infection

Area of Science:

• Virology
• Immunology
• Biochemistry

Background:

• Human Immunodeficiency Virus (HIV) infection is a progressive disease affecting the immune system.
• Monitoring disease progression and treatment effects is crucial for managing HIV.
• Serum thymidine kinase (TK) is an enzyme involved in DNA synthesis, potentially reflecting cellular proliferation and turnover.

Purpose of the Study:

• To investigate the correlation between serum thymidine kinase (TK) levels and the stages of HIV infection.
• To assess the impact of AZT treatment on serum TK levels.
• To evaluate the utility of serum TK as a biomarker in HIV management.

Main Methods:

• Serum TK was measured using the Prolifigen TK-REA assay.
• Patients included HIV-seropositive individuals across various stages (asymptomatic to AIDS), and controls.
• Inclusion criteria allowed for prior EBV, HBV, and CMV infections, excluding acute viral hepatitis or infectious mononucleosis.

Main Results:

• Serum TK levels were elevated from the early seropositive stage of HIV infection, increasing markedly with disease progression.
• AZT treatment led to increased serum TK, which normalized upon dose reduction or discontinuation, suggesting bone-marrow toxicity.
• Serum TK levels showed a close correlation with HIV disease stage.

Conclusions:

• Serum TK is a valuable marker for monitoring HIV infection progression.
• Elevated serum TK during HIV treatment may indicate bone-marrow toxicity, prompting further investigation.
• Serum TK can complement other clinical and laboratory methods for comprehensive HIV patient follow-up.